Financings Roundup

May 2009
BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10
The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about 9.24 percent of the issued and outstanding shares of the company. Proceeds will be used to fund the trial of an oral insulin spray product, and the development of vaccines for cancers and influenzas.


Related Articles

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...

  • Clinic Roundup.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p8 

    This section offers updates on biotechnology sector clinical progress as of May 23, 2013. Acelrx Pharmaceuticals Inc. reported on the results of a Phase III study with its Sufentanil NanoTab patient-controlled analgesia (PCA) system. Agenus Inc. announced the start of a Phase II study with a...

  • American Society of Clinical Oncology.  // BioWorld International;6/3/2009, Vol. 14 Issue 22, p5 

    The article focuses on the results of the Phase I trial of AE37 cancer vaccine presented by Generex Biotechnology Corp. at the annual meeting of the American Society of Clinical Oncology (ASCO) in the U.S. in May 2009. Results indicated that the vaccine is well tolerated and can drive immune...

  • Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials. Boggs, Jennifer // BioWorld Today;4/3/2008, Vol. 19 Issue 65, p3 

    This article reports on the money being raised by Generex Biotechnology Corp. to support the late-stage trials of Oral-lyn, an insulin spray product for Type I and Type II diabetes patients. Eight percent of convertible notes and warrants will be issued by Generex Biotechnology to existing...

  • Research Update.  // PharmaWatch: Biotechnology;Dec2006, Vol. 5 Issue 12, p5 

    The article offers international news briefs related to biotechnology for the year 2006. Neurogen Corp. has started phase I human testing of its leading drug candidate NGD4715, for the treatment of obesity. Genmab AS has initiated a phase I/II study of HuMax-EGFr in combination with...

  • life sciences In Brief.  // Chemical Market Reporter;3/21/2005, Vol. 267 Issue 12, p8 

    The article presents information on recent developments related to life sciences. Astralis Ltd. says that preliminary results from a Phase II study of its product candidate, a novel immuno-stimulatory product for psoriasis, did not meet its primary endpoint. Generex Biotechnology Corp. reports...

  • CLINIC ROUNDUP.  // BioWorld Today;8/11/2008, Vol. 19 Issue 155, p5 

    This section offers news briefs on clinical trials of various medical preparations. Generex Biotechnology Corp. has begun enrolling patients for a Phase I trial employing an immunotherapeutic cancer vaccine. Virax Holdings Ltd. said the South African Medicines Control Council approved the...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • CLINIC ROUNDUP.  // BioWorld Today;5/11/2010, Vol. 21 Issue 90, p2 

    This section offers news briefs on clinical trials including the completion by Generex Biotechnology Corp. of enrollment of patients in its Phase III trial of Generex Oral-lyn and the encouraging pharmacokinetic results obtained by QRxPharma Inc. from its trial of a controlled-release dual-opioid.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics